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DObjectives: To report ‘‘hybrid’’ procedure feasibility and the clinical success of transcatheter paravalvular leak
closure through apical access.
Methods: Seven patients (73.6  6.1 years; 4 men) with severe mitral prosthesis paravalvular leak were
selected. All patients were at high risk for open surgery because of severe comorbidities and heart failure
(New York Heart Association class III-IV).
Results: The defect size was 25  7.8 mm in the long axis and 9.3  2 mm in the short axis. Two defects were
detected in 2 patients. The transapical procedure was performed in a ‘‘hybrid’’ surgery room using minithora-
cotomy and general anesthesia. Three-dimensional transesophageal echocardiography and fluoroscopy were
used for imaging. A total of 19 Amplatzer Vascular Plug III devices (St Jude Medical) were implanted in 7 pa-
tients, 2.7/patient and 1 to 3/fistula. The procedure timewas 150.7 66.8 minutes. In 6 of 7 patients (85.7%), the
paravalvular leak was successfully closed, resulting in no or mild residual regurgitation. One patient had mod-
erate regurgitation despite deployment of 3 Amplatzer Vascular Plug III devices. Two patients required blood
transfusion related to procedural blood loss. The patients were discharged at 15.3  6.5 days and followed
up at 215.7  138.6 days. All but 1 patient reported symptomatic improvement by 1 New York Heart
Association class at follow-up. One patient died 216 days postoperatively.
Conclusions:A ‘‘hybrid approach’’ for transcatheter paravalvular leak closure of mitral prosthesis from the api-
cal route is effective in reducing the regurgitation grade and improving functional capacity in high-risk
patients. Complete closure of the defect was maintained at follow-up in most patients. (J Thorac Cardiovasc
Surg 2014;148:1965-9)Paravalvular leak (PVL) occurs in 3% to 10% of patients
after primary mitral valve replacement.1 Clinically relevant
PVL can present as deterioration in symptoms of heart fail-
ure or hemolytic anemia requiring blood transfusion.
The conventional surgical approach has been open repair
of suture dehiscence or prosthesis replacement2,3; however,
invasive surgical intervention increases the morbidity and
mortality. In addition, the success of surgical PVL repair
can be limited by the presence of a severely calcified
mitral ring or friable surrounding tissue.4
Transcatheter closure of PVL is a less-invasive approach
that negates the need for cardiopulmonary bypass and is,
therefore, an attractive alternative. Several techniques exist
for percutaneous closure of a defect at the mitral prosthesis
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The Journal of Thoracic and Carcrossing of the PVL through transseptal puncture or a
retrograde approach from the left ventricle.
We sought to evaluate a hybrid approach for the percuta-
neous closure of mitral PVL using a transapical approach,
combining the skills of the cardiac surgeon and interven-
tional cardiologist in the ‘‘hybrid room’’ on the beating
heart. The purpose of our study was to report the feasibility
and clinical success of a ‘‘hybrid’’ transcatheter PVL
closure procedure with the Amplatzer Vascular Plug III
(AVP III) device using a transapical route.METHODS
Study Population
From March 2013 to February 2014, 7 consecutive patients with severe
mitral prosthesis PVL were selected for transcatheter closure using the api-
cal approach. All patients were considered by the heart team to be at pro-
hibitive operative risk because of the EuroSCORE II score (mean 11.7 7)
and had been denied surgery by the cardiac surgeon.
All patients had severe paravalvular mitral prosthesis leak accompanied
by symptoms of heart failure (New York Heart Association [NYHA] class
III-IV), and severe pulmonary hypertension (69  15 mm Hg). Three pa-
tients had hemolytic anemia, two of whom were transfusion dependent.
Two patients had undergone 3 and one 4 previous sternotomies for re-do
prosthesis replacement or repair of dehiscence. Three patients had a bio-
prosthetic valve in the mitral valve position. Four patients had concomitant
coronary artery disease and six had chronic kidney impairment. The clin-
ical characteristics are summarized in Table 1.diovascular Surgery c Volume 148, Number 5 1965
Abbreviations and Acronyms
AVP III ¼ Amplatzer Vascular Plug III
CT ¼ computed tomography
HF ¼ heart failure
LV ¼ left ventricular
MR ¼ mitral regurgitation
NYHA ¼ New York Heart Association
PAP ¼ pulmonary artery pressure (by
echocardiography)
PVL ¼ paravalvular leak
TEE ¼ transesophageal echocardiography
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We used 3-dimensional (3D) transesophageal echocardiography (TEE)
and electrocardiography-gated computed tomography (CT) angiography
to determine the size, location, and anatomy of the PVL. CT was used
to evaluate (1) the location of the defect in relation to the surrounding
structures, (2) the location of the left ventricular (LV) apex in relation
to the chest wall. The location of the defect was reviewed, mimicking
the fluoroscopic angles (right anterior oblique 20-30 and left anterior ob-
lique 10-30).
A total of 9 defects producing PVLs were identified in 7 patients. The
median defect size was 25  7.8 mm (range, 6.6-33) in the long axis and
9.3  2 mm (range, 6-12) in the short axis. Two patients had 2 defects.
The location of the leak was described by analyzing the mitral annulus
in a clock-like format from the surgeon’s view7: 3 defects were in the septal
position, 3 in the posterolateral, 1 in the posterior, and 2 in the anterior
aspect of the mitral prosthesis.
All patients provided written informed consent.
AVP III Device
In all patients, we used the AVP III device (St Jude Medical, Plymouth,
Minn), which closely resembles the shape of the PVL. A more detailed
description of the device has been previously reported.8
Transcatheter Closure of PVL
All procedures were jointly performed by a cardiac surgeon and inter-
ventional cardiologist in a ‘‘hybrid room.’’ At our institution, the hybrid
suite is a catheterization facility with a sophisticated fluoroscopy arm
and the capability of the more complex surgical procedures possible in a
standard catheterization suite. With the patient under general anesthesia,
a left lateral thoracotomy in the fifth intercostal space (4-5–cm incision)
was used to expose the apex of the heart. Two standard purse string sutures
were placed, and an echocardiographically guided puncture was per-
formed. Using fluoroscopy, a straight-tip, 0.035-in. Terumo guidewire (Ter-
umo Europe, Heverlee, Belgium) was advanced into the left ventricle and
across the defect into the left atrium. A 7F introducer sheath was advanced
across the defect into the left atrium. Two 0.035-in. wires were then in-
serted to facilitate the introduction of a second 7F sheath if simultaneous
delivery of 2 AVP III devices was required. A third percutaneous coronary
intervention wire, delivered across the defect, was used as a safety wire in
case a third plug would become necessary. 3D TEE and fluoroscopy were
used to navigate the delivery catheter through the leak, to orientate the de-
vice in the defect, and to assess the interaction of the device within the
mitral valve prosthesis ring. Two-dimensional and 3D color Doppler
were used to evaluate the residual regurgitation through the leak after de-
vice implantation. A final decision to release the AVP III device was
made only after final confirmation of a complete seal.1966 The Journal of Thoracic and Cardiovascular SurStudy Endpoints
The study endpoints were the severity of the residual PVL, death from
any cause, heart failure NYHA class, and the necessity for blood transfu-
sions. These parameters were collected after the procedure and at 215.7
 138.6 days (range, 30-364) of follow-up.
Definitions
Transcatheter closure of the PVL around a mitral prosthesis was consid-
ered successful when a complete seal was achieved after implantation of an
AVP III device with no, or mild, residual regurgitation.
Death from any cause was defined as any death in-hospital or at 215 
138.6 days.
The NYHA functional classification was used to assess the severity of
symptoms in relation to physical activity.
Statistical Analysis
Continuous results are reported as the mean  standard deviation. The
categorical data are presented as counts and percentages. Calculations were
performed using the SPSS, version 16.0 (IBM Corp, Armonk, NY).
RESULTS
The transcatheter mitral prosthesis PVL closure time was
150.7  66.8 minutes (range, 70-265). In 6 of 7 patients
(85.7%), the PVL was successfully closed, resulting in
no, or mild, residual regurgitation. In 1 patient, residual
moderate leak was present after complete release of 3
AVP III devices (123 5, 143 5, and 123 5 mm). The pro-
cedure was complicated by embolization of 2 AVP III plugs
to the left atrium; however, these were successfully recap-
tured and reimplanted using the same access site.
A total of 19 AVP III devices (2.7/patient, range, 1-5; 1-3/
fistula) were implanted in 7 patients. Five devices were im-
planted in 1 of the patients with 2 defects (Figure 1). The
number of devices implanted in each case is listed in
Table 2. Two patients required blood transfusion related
to procedural blood loss.
The patients were discharged at 15.3  6.5 days (range,
7-24) after defect closure.
Follow-up
One patient was readmitted with severe gastrointestinal
bleeding requiring blood transfusion and subsequently
died of advanced heart failure and severe anemia at 216
days after the procedure.
An improvement from NYHA class III-IV to class II was
maintained in 3 patients (42.9%); and 3 patients remained
in NYHA class III (Table 2).
In 2 patients with blood transfusion-dependent hemolytic
anemia, the frequency of blood transfusions decreased post-
operatively. In 1 of them, incomplete defect sealing resulted
in moderate residual regurgitation.
DISCUSSION
The principle findings of the present clinical study were
that complete closure of the paravalvular mitral prosthesis
defect, resulting in no or mild residual leak, was achievedgery c November 2014
TABLE 1. Baseline characteristics
Characteristic
Pt. no.
1 2 3 4 5 6 7
Age (y) 85 77 72 72 75 63 73
Gender Male Male Female Female Female Male Male
Previous revascularization Yes Yes No No Yes Yes Yes
Previous pacemaker Yes No Yes No Yes Yes Yes
Previous IE No No Yes No No No No
Previous surgery for PVL No No Yes Yes No No Yes
Sternotomies (n) 1 1 3 3 1 1 4
Interval since valve surgery (mo) 11 12 3 110 70 7 102
Atrial fibrillation No Yes Yes Yes Yes No Yes
Renal insufficiency Yes Yes Yes Yes No Yes Yes
Blood transfusion dependent No No No Yes No No Yes
NYHA class III IV III IV IV III III
Log EuroSCORE II 9.5 7.6 21 9.3 22.2 3.5 9.1
LVEF (%) 35 55 55 50 20 60 50
PAP (mm Hg) 66 90 77 No 55 50 76
Pt. no., Patient number; IE, infective endocarditis; PVL, paravalvular leak; NYHA, New York Heart Association; EuroSCORE, European System for Cardiac Operative Risk Eval-
uation; LVEF, left ventricular ejection fraction; PAP, systolic pulmonary artery pressure.
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immediately after the procedure, and 71.4% at 215.7 
138.6 days. Also, closure of the defect resulted in substan-
tial improvement in heart failure symptoms by
1 functional class in 5 of the 7 patients (71.4%) at
215.7  138 days, suggesting the durability of the
procedure.
Other investigators have reported their experience with
percutaneous closure of mitral prosthesis PVLs using a va-
riety of approaches and techniques. Complete closure of the
defect has been achieved in most patients, with success rates
ranging from 59% to 82%.9-11
A mitral PVL defect can be sealed using an antegrade
approach through an atrial transseptal puncture or a retro-
grade approach from the left ventricle. The effectivenessFIGURE 1. Complete sealing of 2 paravalvular mitral prosthesis defects wa
The Journal of Thoracic and Carof the antegrade approach could potentially be limited by
the anatomic location of the defect. High success rates
(83%) have been reported with posteriorly located defects9;
however, the outcomes have been less favorable when the
defect is in the septal or anterior position.
Consistent with other investigators,12,13 we found the
transapical approach to be both practical and feasible,
with complete closure achieved in >85% of patients.
Unlike the antegrade transseptal approach, which will be
constrained by the anatomic location of the defect and the
left atrial size, the transapical approach allows access to
defects in all anatomic locations and successful device
delivery. Thourani and colleagues13 reported successful
transapical closure of the PVL in 3 patients using the Am-
platzer ventricular septal defect occluder and Amplatzers achieved after implantation of 5 Amplatzer Vascular Plug III devices.
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TABLE 2. Treatment and follow-up data per patient
Pt.
no.
Age
(y)
Baseline Procedure Follow-up
Previous
sternotomy
NYHA
class
Defects
(n)
Defect location,
size (mm)
PVL
grade
AVP III devices (n);
size (mm)
PVL
grade
Duration
(d) PVL
NYHA
class MACE
1 83 1 III 1 Septal, 16 3 7 Severe 2 devices; 8 3 4, 14 3 5 Mild 320 Mild II —
2 77 1 IV 1 Septal, 21 3 12 Severe 2 devices; 12 3 5, 8 3 4 None 329 Mild III —
3 72 3 III 2 Posterolateral, 32 3 9 Severe 3 devices; 12 3 5, 12 3 5,
8 3 4
Mild 364 Moderate III Re-do
planned
4 72 3 IV 2 Anterior, size unknown;
posterior, size unknown
Severe 5 devices; 14 3 5, 10 3 5,
10 3 5, 12 3 5, 10 3 5
None 201 None III Death
5 75 1 IV 1 Posterolateral, 33 3 9 Severe 3 devices; 12 3 5, 10 3 5,
14 3 5
None 41 Mild III —
6 63 2 III 1 Anterior, 6.5 3 6 Severe 12 3 5 None 170 None II —
7 73 4 III 1 Septal, 20 3 10 Severe 3 devices; 12 3 5, 12 3 5,
14 3 5
Moderate 29 Moderate II —
Pt. no., Patient number; NYHA, New York Heart Association; PVL, paravalvular leak; AVP, Amplatzer Vascular Plug; MACE, major adverse cardiac event.
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leageus12 achieved an excellent seal with AVP III devices
in 6 of 7 patients in whom an initial transvascular approach
had failed or seemed unfeasible.
Just as with Smolka and colleagues,12 we used>1 AVP
III plug to seal the defect channel; however, our patient se-
lection criteria were slightly different. In our series, a hybrid
approach was used from the outset. We believe this resulted
in a shorter procedure, which, in patients with multiple co-
morbidities, might translate into quicker recovery and
improved long-term outcomes. Also, preprocedural CT im-
aging was performed in all our patients, providing useful
additional information to 3D-TEE. The procedure was
guided by 3D-TEE and fluoroscopy; however, preproce-
dural CT imaging offered a number of additional advan-
tages, including determining the precise anatomic location
of the defect and whether it was easily visible; determining
the anatomic location of the LV apex relative to the chest
wall, which proved essential for access planning; and deter-
mining the optimal access and deployment angles to be used
angiographically. Additional clinical studies should reveal
whether new imaging technologies combining real-time
3D-TEE synchronized with angiographic views would
facilitate the procedure even more.
In all cases, we were able to cross the defect channel,
including the patient with a serpiginous tunnel, and deploy
the devices across the leak. We found that proximity to the
defect (10-15 cm from the apex) gave better control during
device delivery, positioning, and deployment. Apical access
also facilitated the manipulation of 2 to 3 devices simulta-
neously, which could potentially facilitate the closure of
larger defects and the delivery of several devices, if required
(Figure 1). Also, access site bleeding (LV apex) can be
easily controlled. No late complications from ventricular
puncture were observed.
We believe that a hybrid approach to PVL closure should
be considered for high-risk patients, in particular, those in
whom conventional surgery has failed to repair the1968 The Journal of Thoracic and Cardiovascular Surdehiscence. Also, this approach can be used for defects in
all anatomic locations relative to the mitral prosthesis.
The only contraindications to the procedure would be the
presence of LV thrombus, a calcified LVapex, or an unstable
prosthesis due to significant dehiscence.
At present, no device with indications for PVL closure
has been approved. Experience with the AVP III device
has been limited to case reports and small case series.14
However, the ellipsoidal shape, design, and available di-
mensions of the AVP III seem to closely match the defects
associated with mitral prostheses. Therefore, interference
with the function of the mitral prosthesis can be avoided
by rotating the device under direct vision using real-time
3D-TEE. In our series, no interference with the prosthesis
was noted after device deployment. Our results are consis-
tent with those from other investigators, supporting this de-
vice application for sealing a periprosthetic defect and
contribute to up-to-date available clinical experience.14-17
In the last patient (Table 2), we were not able to achieve
complete success because of the presence of a large, oval-
shaped defect, measuring 20 3 10 mm on CT. It might be
that an alternative device with a more oval shape would
have worked better in this patient.
Complete sealing was well maintained at follow-up in
most of our patients (71.4%) and was associated with an
improvement in NYHA functional class. Improved func-
tional status to NYHA class II was maintained at the last
follow-up visit in 3 patients (42.9%). The remaining 3 pa-
tients (Table 2) had limited functional capacity (NYHA
class III) owing to the recurrence of a moderate leak be-
tween 2 contiguous implanted devices (patient 3), the pres-
ence of poor left ventricular systolic function with an
ejection fraction of 25% (patient 5), and mild improvement
from NYHA class IV to class III associated with defect
closure (patient 2). The recurrence of PVL in patient 3
might have resulted from late displacement of the AVP III
devices and/or additional progression of the prosthesis
dehiscence.gery c November 2014
Davidavicius et al Acquired Cardiovascular Disease
A
C
DAt present, the application of transcatheter PVL closure
is limited to those patients at high surgical risk. Almost
one half of the patients (43%) in our series had previously
undergone surgery for dehiscence correction. Moreover, in
3 patients who had previously undergone 3 to 4 sternoto-
mies, this was the only treatment option remaining. In 2
patients with blood transfusion-dependent anemia, a
reduction occurred in the frequency of the blood
transfusions.
Study Limitations
The AVP III device has not been approved by the Food
and Drug Administration and is not available for use in
the United States. The small sample size our study was
another limitation, and additional studies, ideally with a
randomized controlled design, are needed to assess the
advantage of this technique compared with percutaneous
transvascular repair.
CONCLUSIONS
Our results have shown that a hybrid approach for trans-
catheter mitral prosthesis PVL closure using the transapi-
cal approach is practical, feasible, and effective in
reducing the degree of mitral regurgitation and improving
the functional capacity of high-risk patients. Effective
defect sealing was maintained at follow-up in most of
our patients.
We acknowledge Dr Joanne Shannon and Lon Annest for their
help in manuscript preparation.
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